文献速递肝病

非酒精性脂肪性肝病的无创肝纤维化评估

Noninvasive Assessment of Liver Fibrosis in NAFLD.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-04-14

非酒精性脂肪性肝病(NAFLD)全球约影响十亿人,肝纤维化程度是临床结局最强预测因子。肝活检虽为参考标准,但因有创、罕见严重并发症和采样变异而不适合大规模筛查。本综述提出无创工具在临床实践和药物研发中开发与整合的路线图,讨论其开发验证原则及在诊断、风险分层、结局预测、纤维化监测和治疗反应评估中的应用。

要点

  • NAFLD全球约影响十亿人,肝纤维化严重程度是临床结局最强预测因子。
  • 肝活检为参考标准,但因有创、罕见严重并发症和采样变异不适合大规模人群评估。
  • 无创方法基于血清生物标志物定量或超声/磁共振弹性成像测肝硬度。

核心结论

  • 本综述为NAFLD无创工具在临床实践和药物研发中的未来开发与整合提供路线图。

研究设计与样本

  • 综述,讨论无创工具的开发与验证原则及其在临床实践和药物研发中的应用。

主要发现

  • NAFLD全球约影响十亿人,呈缓慢进展,部分患者可进展为肝硬化、肝细胞癌和终末期肝病。
  • 肝纤维化严重程度是临床结局最强预测因子。
  • 肝活检为参考标准,但因有创、罕见严重并发症和采样变异不适合大规模人群评估。
  • 无创方法基于血清样本生物标志物定量或超声/磁共振弹性成像测肝硬度。

关键数值与推荐

  • 无创工具应用包括NAFLD诊断、基层和肝病专科风险分层、长期肝脏相关和非肝脏相关结局预测、纤维化进展与逆转监测及对未来治疗的反应评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver-related morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a slowly progressive disease that may evolve in a subset of patients toward cirrhosis, hepatocellular carcinoma, and end-stage liver disease. Liver fibrosis severity is the strongest predictor of clinical outcomes. The emergence of effective therapeutics on the horizon highlights the need to identify among patients with NAFLD, those with severe fibrosis or cirrhosis, who are the most at risk of developing complications and target them for therapy. Liver biopsy has been the reference standard for this purpose. However, it is not suitable for large-scale population evaluation, given its well-known limitations (invasiveness, rare but severe complications, and sampling variability). Thus, there have been major efforts to develop simple noninvasive tools that can be used in routine clinical settings and in drug development. Noninvasive approaches are based on the quantification of biomarkers in serum samples or on the measurement of liver stiffness, using either ultrasound- or magnetic resonance-based elastography techniques. This review provides a roadmap for future development and integration of noninvasive tools in clinical practice and in drug development in NAFLD. We discuss herein the principles for their development and validation, their use in clinical practice, including for diagnosis of NAFLD, risk stratification in primary care and hepatology settings, prediction of long-term liver-related and non-liver-related outcomes, monitoring of fibrosis progression and regression, and response to future treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sanyal AJ, Castera L, Wong VW, et al. Noninvasive Assessment of Liver Fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023. PMID: 37062495. doi:10.1016/j.cgh.2023.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。